The cost-effectiveness of achieving asthma control with the combination products salmeterol/fluticasone propionate or formoterol/budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001
Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice Source: Eur Respir J 2001; 18: Suppl. 33, 348s Year: 2001
Long-term clinical management with the salmeterol/fluticasone propionate combination, fluticasone propionate and sameterol in a 'real-life' study Source: Eur Respir J 2003; 22: Suppl. 45, 236s Year: 2003
Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 49s Year: 2003
Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life Source: Eur Respir J 2003; 22: Suppl. 45, 51s Year: 2003
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Survival in COPD patients after regular use of fluticasone propionate and salmeterol Source: Eur Respir J 2003; 21: 559-560 Year: 2003
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Improvements in FEV1 and symptoms in poorly-reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003
A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD Source: Eur Respir J 2014; 43: 763-772 Year: 2014
Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004
Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007
Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Asthma exacerbation with fluticasone propionate/formoterol fumarate combination therapy versus its individual components Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012